April 2014

Attendees of the Urology Joint Advocacy Conference were asked to focus on four goals as they left the Washington, DC gathering to meet with congressmen and senators on Capitol Hill.

One of the ongoing debates in US politics involves the pros and cons of big government versus small government: Does big automatically equal bureaucracy and groupthink while small inherently fosters individual creativity and enterprise?

Our country is facing present and future fiscal challenges that have never been encountered before in our nation's history. Our major entitlement programs are not new.

New prostate cancer screening guidelines that seek to balance overtreatment concerns with the need to preserve gains in curbing prostate cancer mortality were unveiled at the National Comprehensive Cancer Network's 19th Annual Conference.

In urology, we are faced with very difficult and challenging times.

A recent study that followed men newly diagnosed with localized prostate cancer for a median 18 years found that immediate radical prostatectomy significantly cut death rates as compared with watchful waiting with treatment upon progression, especially in men with intermediate-risk disease.

Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis

A trial (NCT01582672) that will pair a targeted treatment with a vaccine therapy for firstline treatment of renal cell carcinoma (RCC) is recruiting at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

Despite being quite popular, the dietary supplements vitamin E and selenium do not protect men from developing prostate cancer, and in fact greatly increase risk in certain patients if taken at doses higher than those recommended

Richard S. Pelman, MD, Juan A. Reyna, MD, and David F. Penson, MD, all large urology organization leaders, cited managing bureaucracy, PSA screening, and in-office ancillaries as top priorities.

Obesity increases the chance that someone will get the clear-cell form of renal cell carcinoma (ccRCC). But once an obese patient has the disease, he's likely to survive longer than a non-obese patient.